Patents by Inventor Adrian Bot

Adrian Bot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11491187
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: November 8, 2022
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Publication number: 20220265719
    Abstract: The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade).
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Inventors: Adrian Bot, Szu-Ting Chou, Vicki Plaks, Soumya Poddar, John Rossi
  • Publication number: 20220169694
    Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.
    Type: Application
    Filed: February 20, 2021
    Publication date: June 2, 2022
    Inventors: Adrian Bot, John Rossi, Vicki Plaks, Szu-Ting Chou, William Go, Jenny Jiyun Kim
  • Publication number: 20220016165
    Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.
    Type: Application
    Filed: February 20, 2021
    Publication date: January 20, 2022
    Inventors: Adrian Bot, Michael David Mattie
  • Publication number: 20210161959
    Abstract: Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 3, 2021
    Inventors: ADRIAN BOT, JOHN ROSSI
  • Publication number: 20190314410
    Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining an effective dose of a T cell immunotherapy.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventors: John M. Rossi, Adrian Bot
  • Patent number: 10322146
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 18, 2019
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Publication number: 20180369283
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: April 10, 2018
    Publication date: December 27, 2018
    Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Publication number: 20180344767
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 6, 2018
    Applicants: Kite Pharma, Inc., The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Patent number: 9855298
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 2, 2018
    Assignees: Kite Pharma, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Publication number: 20170368101
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: July 13, 2017
    Publication date: December 28, 2017
    Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Publication number: 20160346326
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Applicants: Kite Pharma, Inc., National Cancer Institute
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • Patent number: 8809290
    Abstract: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-?, IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: August 19, 2014
    Assignee: Multicell Immunotherapeutics, Inc.
    Inventors: Adrian Bot, Lilin Wang, Dan Joseph Smith, William Joseph Phillips, Jr., Luis A. Dellamary
  • Patent number: 8354380
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: January 15, 2013
    Assignee: MannKind Corporation
    Inventors: Liping Liu, Adrian Bot, David C. Diamond
  • Publication number: 20120189645
    Abstract: The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that compromises a B cell and a T cell component.
    Type: Application
    Filed: February 18, 2010
    Publication date: July 26, 2012
    Applicant: Multicell immunotherapeutics, Inc. (Formally ASTRAL, INC.)
    Inventors: Adrian Bot, Lilin Wang, Luis Dellamary, Dan Smith, Bill Phillips
  • Publication number: 20110301327
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Application
    Filed: February 28, 2011
    Publication date: December 8, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Liping Liu, Adrian Bot, David C. Diamond
  • Publication number: 20110274705
    Abstract: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-?, IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process.
    Type: Application
    Filed: April 1, 2011
    Publication date: November 10, 2011
    Inventors: Adrian Bot, Lilin Wang, Dan Smith, Bill Phillips
  • Publication number: 20100303842
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Application
    Filed: March 17, 2009
    Publication date: December 2, 2010
    Applicant: MANNKIND CORPORATION
    Inventors: Liping Liu, Adrian Bot, Jian Gong, David Diamond
  • Patent number: 7605227
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: October 20, 2009
    Assignee: MannKind Corporation
    Inventors: Liping Liu, Adrian Bot, David C. Diamond
  • Publication number: 20090169571
    Abstract: The present application is directed to the use of dsRNA and/or ssRNA for the purpose of inducing apoptosis or cell death in proliferating cells. Specifically, low molecular weight and high molecular weight dsRNA and ssRNA are shown to induce apoptosis and/or cell death in proliferating cells, to arrest proliferation of transformed cells or tumor cells and to cause rapid induction of the cytokine TNF-alpha and/or also induce production of IL-12 which directs a Th-1 response.
    Type: Application
    Filed: November 14, 2008
    Publication date: July 2, 2009
    Applicant: Multicell Immunotherapeutics, Inc.
    Inventors: Dan Smith, Adrian Bot